

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently Amended) A composition comprising
an immunostimulatory nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, wherein the immunostimulatory nucleic acid has a nucleotide backbone comprising at least one phosphorothioate modification, and wherein the immunostimulatory nucleic acid comprises a C
~~of at least one of the four CpG motifs~~ motif which is unmethylated.
2. (Original) The composition of claim 1, wherein the immunostimulatory nucleic acid molecule consists of the nucleotide sequence of SEQ ID NO:1.
3. (Original) The composition of claim 1, further comprising an antigen.
4. (Original) The composition of claim 3, wherein the antigen is selected from the group consisting of a microbial antigen, a cancer antigen, and an allergen.
5. (Original) The composition of claim 4, wherein the microbial antigen is selected from the group consisting of a bacterial antigen, a viral antigen, a fungal antigen and a parasitic antigen.
6. (Original) The composition of claim 3, wherein the antigen is encoded by a nucleic acid vector.
7. (Original) The composition of claim 3, wherein the nucleic acid vector is separate from the immunostimulatory nucleic acid.
8. (Original) The composition of claim 3, wherein the antigen is a peptide antigen.

9. (Original) The composition of claim 1, further comprising an adjuvant.
10. (Original) The composition of claim 9, wherein the adjuvant is a mucosal adjuvant.
11. (Original) The composition of claim 1, further comprising a cytokine.
12. (Currently Amended) The composition of claim 1, further comprising a therapeutic agent selected from the group consisting of an anti-microbial agent, an anti-cancer agent, and an allergy/asthma medicament.
13. (Original) The composition of claim 12, wherein the anti-microbial agent is selected from the group consisting of an anti-bacterial agent, an anti-viral agent, an anti-fungal agent, and an anti-parasite agent.
14. (Withdrawn) The composition of claim 12, wherein the anti-cancer agent is selected from the group consisting of a chemotherapeutic agent, a cancer vaccine, and an immunotherapeutic agent.
15. (Withdrawn) The composition of claim 12, wherein the allergy/asthma medicament is selected from the group consisting of PDE-4 inhibitor, bronchodilator/beta-2 agonist, K⁺ channel opener, VLA-4 antagonist, neurokin antagonist, TXA₂ synthesis inhibitor, xanthanine, arachidonic acid antagonist, 5 lipoxygenase inhibitor, thromboxin A₂ receptor antagonist, thromboxane A₂ antagonist, inhibitor of 5-lipoxygenase activation protein, and protease inhibitor.
16. – 17. (Canceled)
18. (Previously Presented) The composition of claim 1, wherein the nucleotide backbone is chimeric.

19. (Previously Presented) The composition of claim 1, wherein the nucleotide backbone is entirely modified.

20. (Previously Presented) The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

21. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is free of methylated CpG dinucleotides.

22. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid includes more than four CpG motifs.

23. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is T-rich.

24. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid includes a poly-T sequence.

25. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid includes a poly-G sequence.

26. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated for oral administration.

27. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated as a nutritional supplement.

28. (Previously Presented) The composition of claim 27, wherein the nutritional supplement is formulated as a capsule, a pill, or a sublingual tablet.

29. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated for local administration.

30. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated for parenteral administration.

31. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated in a sustained release device.

32. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is formulated for delivery to a mucosal surface.

33. (Previously Presented) The composition of claim 1, wherein the mucosal surface is selected from the group consisting of an oral, nasal, rectal, vaginal, and ocular surface.

34. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid stimulates a mucosal immune response.

35. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid stimulates a systemic immune response.

36. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to stimulate a mucosal immune response.

37. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to stimulate a systemic immune response.

38. (Previously Presented) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to stimulate an innate immune response.

39. (Currently Amended) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to ~~treat or prevent an infectious disease~~ stimulate an immune response against an infectious agent.

40. (Withdrawn) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to treat or prevent an allergy.

41. (Withdrawn) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to treat or prevent asthma.

42. (Withdrawn) The composition of claim 1, wherein the immunostimulatory nucleic acid is provided in an amount effective to treat or prevent a cancer.

43. (Previously Presented) The composition of claim 31, wherein the sustained release device is a microparticle.

44. (Currently Amended) The composition of claim 39, wherein the infectious ~~disease agent~~ agent is a herpes simplex virus ~~infection~~.

45. (Withdrawn) A method for stimulating an immune response in a subject in need thereof comprising

administering to a subject an immunostimulatory nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, in an amount effective to stimulate an immune response.

46.-95. (Cancelled)

96. (Withdrawn) A method for preventing disease in a subject, comprising administering to the subject an immunostimulatory nucleic acid on a regular basis to prevent disease in the subject, wherein the immunostimulatory nucleic acid has a nucleotide sequence comprising SEQ ID NO:1.

97. (Withdrawn) A method for inducing an innate immune response, comprising administering to the subject an immunostimulatory nucleic acid in an amount effective for activating an innate immune response, wherein the immunostimulatory nucleic acid has a nucleotide sequence comprising SEQ ID NO:1.

98. (Withdrawn) A method for identifying an immunostimulatory nucleic acid comprising measuring a control level of activation of an immune cell population contacted with an immunostimulatory nucleic acid comprising a nucleotide sequence of SEQ ID NO:1, measuring a test level of activation of an immune cell population contacted with a test nucleic acid, and comparing the control level of activation to the test level of activation, wherein a test level that is equal to or above the control level is indicative of an immunostimulatory nucleic acid.

99. (Currently Amended) A composition comprising an immunostimulatory nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, wherein the immunostimulatory nucleic acid is ~~equal to or less than~~ 21-100 nucleotides in length, and wherein the C of the four CpG motifs are unmethylated.

100. (Previously Presented) A composition comprising an immunostimulatory nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, and an antigen, wherein the C of the four CpG motifs are unmethylated.

101. (Previously Presented) A composition comprising
an immunostimulatory nucleic acid comprising the nucleotide sequence of SEQ ID NO:1,
wherein the immunostimulatory nucleic acid is single stranded, and wherein the C of the four CpG
motifs are unmethylated.

102. (Previously Presented) A composition comprising
an immunostimulatory nucleic acid molecule consisting of the nucleotide sequence of SEQ
ID NO:1, wherein the C of the four CpG motifs are unmethylated.